CD1a, human (MTB1)

Catalogue number: CD1A-MTB

Product Type Primary Antibodies
Units1 ml
Application Immunohistochemistry (paraffin)

Clone MTB1 labels cortical thymocytes, Langerhans-Cells in the skin as well as interdigitating cells in the dermis and in squamous epithelia of tonsils. It labels also a small group of cells outside the germinal center of tonsils, which indicates a possible cross-reactivity with CD1b. Up to now CD1 has been identified as five different variants encoded by 5 different genes (they are designed as CD1a, b, c, d and e). CD1 is exprimed by cortical thymocytes, Langerhans cells in epithelia and dendritic cells. Usually it doesn't occur in mature peripheral blood cells, but is exprimed intra-cytoplasmatically in activated T-cells. CD1a plays a role in the detection of graft versus host reaction, in the detection of interdigitating cells in artereosclerotic lesion and in asthmatic inflammation. Human CD1a, possible cross-reactivity with CD1b.


Immunogen: Recombinant protein corresponding to full length extracellular CD1a domain

Cell culture supernatant containing 0.09% sodium azide as preservative

Purification Method: Cell culture supernatant containing 0.09% sodium azide as preservative

Secondary Reagents: We recommend the use of BIOLOGO's Universal Staining System DAB (Art. No. DA005) or AEC (Art. No. AE005).


Species Reactivity: Human


Incubation Time: 60 min at RT

Working Concentration: (liquid conc.) 1:20-1:40

Pre-Treatment: Pre-treatment of formaldehyde-fixed material should be treated with Unmasking Solution E, TRIS-buffered EDTA pH 9 (Art. No. DE006) at 96-100°C

Positive Control: Thymus


*These antibodies are intended for in vitro research use only. They must not be used for clinical diagnostics and not for in vivo experiments in humans or animals. ** The preservative sodium azide is known to be poisonous and potentially hazardous to health. It should be handled only by trained staff. Despite of the product's low azide concentration it must be handled with care. Dispose according to regional rules!

1. Hunger RE, Sieling PA, Ochoa MT, Sugaya M, Burdick AE, Rea TH, Brennan PJ, Belisle JT, Blauvelt A, Porcelli SA, Modlin RL. Langerhans cells utilize CD1a and langerin to efficiently present nonpeptide antigens to T cells. J Clin Invest. 2004 Mar;113(5):701-8. 2. Takagi S, Miyagawa S, Ichikawa E, Soeda J, Miwa S, Miyagawa Y, Iijima S, Noike T, Kobayashi A, Kawasaki S. Dendritic cells, T-cell infiltration, and Grp94 expression in cholangiocellular carcinoma. Hum Pathol. 2004 Jul;35(7):881-6. 3. Poindexter NJ, Sahin A, Hunt KK, Grimm EA. Analysis of dendritic cells in tumor-free and tumor-containing sentinel lymph nodes from patients with breast cancer. Breast Cancer Res. 2004;6(4):R408-15. 4. Mazal PR, Hainfellner JA, Preiser J, Czech T, Simonitsch I, Radaszkiewicz T, Budka H. Langerhans cell histiocytosis of the hypothalamus: diagnostic value of immunohistochemistry. Clin Neuropathol. 1996 Mar-Apr;15(2):87-91. 5. Bobryshev YV, Lord RS. Langhans cells of human arterial intima: uniform by stellate appearance but different by nature. Tissue Cell. 1996 Apr;28(2):177-94.